CSF1R and benign prostatic hyperplasia: Disruption of this axis via sunitinib, CSF1R silencing, or ligand neutralization was associated with reduced fibroblast-induced epithelial proliferation in vitro and attenuated prostate enlargement in an androgen-induced BPH mouse model.